Brooth.

- 23. (New) The method according to claim 22, wherein the addictive drug is selected from the group consisting of an opioid and nicotine and the corticosteroid receptor agonist is selected from dexamethasone and corticosterone.
- 24. (New) The method according to claim 23, wherein the addictive drug is an opioid.

REMARKS

The Claim Amendments

Applicant has canceled claim 11 without prejudice. Applicant reserves the right to pursue the canceled subject matter in subsequent applications that claim benefit from the instant application.

Applicant has amended claim 4 to cancel the recitation of alcoholism.

Applicant has amended claims 5 and 7 to add the word "agonist" following "corticosteroid receptor" and "mineralocorticoid receptor" to improve the form of the claims.

Applicant has amended claim 8 by adding the "receptor agonist" following "corticosteroid" to improve the form of the claim.

Applicant has added claims 12-24. Support for claims 12-24 may be found throughout the specification. See, for example, page 14, line 25 to page 15, line 7 and page 15, lines 17-32.

None of these amendments adds new matter. Their entry is requested.



CONCLUSION

In view of the foregoing remarks, applicant respectfully requests consideration and early allowance of the pending claims.

The Examiner is invited to telephone applicant's representatives regarding any matter that may be handled by telephone to expedite allowance of the pending claims.

Respectfully submitted,

James F. Haley, Jr. (Reg. No. 27,794)

Karen Mangasarian (Reg. No. 43,772) Attorneys for Applicant

c/o FISH & NEAVE

1251 Avenue of the Americas New York, New York 10020 Tel.: (212) 596-9000

T Hereby Certify that this Correspondence is being Beposited with the U.S. Postal Sprvice as First Class Mail in an Envelope Addressed to: ASSISTANT COMMISSIONER FOR PATENTS: - F. a. Boy 2327 AMUNICAL FA 2322an